Multiprofile Hospital For Active Treatment Sveti Ivan Rilski 2003 OOD

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease4 trials
• High blood pressure3 trials
• Type 2 diabetes3 trials
• Stroke2 trials
• Asthma1 trial
• COPD1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Heart failure1 trial
• Hepatitis B1 trial
• Obesity1 trial

Phase

• Phase 312 trials

Status

• Completed6 trials
• Recruiting5 trials
• Active, not recruiting1 trial

Lead sponsor

• AstraZeneca7 trials
• Boehringer Ingelheim2 trials
• Bayer1 trial
• Janssen Research & Development, LLC1 trial
• Opella Healthcare Group S.A.S.1 trial

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

  NCT07664553· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· AstraZeneca· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes3 recruiting
• Chronic kidney disease2 recruiting
• High blood pressure2 recruiting
• Heart failure1 recruiting

Closed trials

• Completed

  Essentiale® liquid once-daily Phase III study

  2025-521678-32-00· Phase 3· Opella Healthcare Group S.A.S.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source